National Institute on Drug Abuse; Notice of Closed Meetings, 9790-9791 [2020-03333]
Download as PDF
<![CDATA[
9790
Federal Register / Vol. 85, No. 34 / Thursday, February 20, 2020 / Notices
Emphasis Panel; Translational Neural, Brain,
and Pain Relief Devices.
Date: March 19–20, 2020.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: Canopy by Hilton, 940 Rose Avenue,
North Bethesda, MD 20852.
Contact Person: Diana M. Cummings, Bs,
Ph.D., Scientific Review Officer, Scientific
Review Branch, National Institute of
Neurological Disorders and Stroke, NIH NSC,
6001 Executive Blvd., Suite 3208, Bethesda,
MD 20892, cummingsdi@ninds.nih.gov.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; NIH Blueprint for
Neuroscience R25 Program on Translational
Devices.
Date: March 20, 2020.
Time: 12:30 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: Canopy by Hilton, 940 Rose Ave.,
North Bethesda, MD 20852.
Contact Person: Diana M. Cummings, Bs,
Ph.D., Scientific Review Officer, Scientific
Review Branch, National Institute of
Neurological Disorders and Stroke, NIH NSC,
6001 Executive Blvd., Suite 3208, Bethesda,
MD 20892, cummingsdi@ninds.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: February 13, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–03331 Filed 2–19–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
lotter on DSKBCFDHB2PROD with NOTICES
Center for Scientific Review;
Cancellation of Meeting
Notice is hereby given of the
cancellation of the Center for Scientific
Review Special Emphasis Panel,
Cellular, Molecular and Integrative
Reproduction Study Section, February
20, 2020, 10:00 a.m. to February 20,
2020, 12:00 p.m., Embassy Suites
Alexandria Old Town, 1900 Diagonal
Road, Alexandria, VA 22314 which was
published in the Federal Register on
January 27, 2020, 85 FR 4672.
Meeting is being cancelled.
Dated: February 13, 2020.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–03286 Filed 2–19–20; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
19:48 Feb 19, 2020
Jkt 250001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Microbiology,
Infectious Diseases and AIDS Initial Review
Group; Microbiology and Infectious Diseases
Research Committee.
Date: February 27–28, 2020.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The William F. Bolger Center, 9600
Newbridge Drive, Potomac, MD 20854.
Contact Person: Amir E. Zeituni, Ph.D.,
Scientific Review Program, Division of
Extramural Activities, National Institute of
Allergy and Infectious Diseases, National
Institutes of Health, 5601 Fishers Lane, RM
3G51, Rockville, MD 20852–9823, 301–496–
2550, amir.zeituni@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: February 13, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–03330 Filed 2–19–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Development of Clinical Outcome
Assessments for Clinical Trials in Substance
Use Disorders as FDA-qualified Drug
Development Tools (U01 Clinical Trial
Optional).
Date: March 6, 2020.
Time: 1:30 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center (NSC), Building 6001
Executive Boulevard, Room 4235, Rockville,
MD 20852 (Telephone Conference Call).
Contact Person: Gerald L. McLaughlin,
Ph.D., Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, National Institutes
of Health, 6001 Executive Boulevard, Room
4235, MSC 9550, Bethesda, MD 20892–9550,
301–827–5819, gm145a@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Workshops on the Use of Adolescent Brain
Cognitive Development (ABCD) Data (R25
Clinical Trial Not Allowed).
Date: March 16, 2020.
Time: 1:00 p.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center (NSC) Building, 6001
Executive Boulevard, Room 4229, Rockville,
MD 20852 (Telephone Conference Call).
Contact Person: Susan O. McGuire, Ph.D.,
Scientific Review Officer, Office of
Extramural Affairs, National Institute on
Drug Abuse, National Institutes of Health,
6001 Executive Boulevard, Room 4245,
Rockville, MD 20852, 301–435–1426,
mcguireso@mail.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Research Networks for the Study of Recovery
Support Services for Persons Treated with
Medications for Opioid Use Disorder (R24
Clinical Trial Optional).
Date: March 17, 2020.
Time: 12:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center (NSC) Building, 6001
Executive Boulevard, Room 4235, Rockville,
MD 20852 (Telephone Conference Call).
Contact Person: Gerald L. McLaughlin,
Ph.D., Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, National Institutes
of Health, 6001 Executive Boulevard, Room
E:\FR\FM\20FEN1.SGM
20FEN1
Federal Register / Vol. 85, No. 34 / Thursday, February 20, 2020 / Notices
4235, MSC 9550, Bethesda, MD 20892–9550,
301–827–5819, gm145a@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: February 13, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–03333 Filed 2–19–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
lotter on DSKBCFDHB2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Small
Business: Non-HIV Microbial Vaccine
Development.
Date: March 12, 2020.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Catamaran Resort, 3999 Mission
Boulevard, San Diego, CA 92109.
Contact Person: Andrea Keane-Myers,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4218,
Bethesda, MD 20892, 301–435–1221,
andrea.keane-myers@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Small
Business: Topics Non-HIH Microbial Vaccine
Development.
Date: March 12, 2020.
Time: 5:00 p.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Catamaran Resort, 3999 Mission
Boulevard, San Diego, CA 92109.
Contact Person: Scott Jakes, Ph.D.,
Scientific Review Officer, Center for
VerDate Sep<11>2014
19:48 Feb 19, 2020
Jkt 250001
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4198,
MSC 7812, Bethesda, MD 20892, 301–495–
1506, jakesse@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, PAR 17–
190: Maximizing Investigators’ Research
Award for Early Stage Investigators (R35).
Date: March 19–20, 2020.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, Bethesda, MD 20814.
Contact Person: Michael Eissenstat, Ph.D.,
Scientific Review Officer, BCMB IRG, Center
for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4166,
MSC 7806, Bethesda, MD 20892, 301–435–
1722, eissenstatma@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Small
Business: Biomedical Sensing, Measurement
and Instrumentation.
Date: March 19–20, 2020.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bahia Resort Hotel, 998 West
Mission Bay Drive, San Diego, CA 92109.
Contact Person: Inna Gorshkova, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, 301–435–1784, gorshkoi@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Small
Business: Health Informatics.
Date: March 19–20, 2020.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The William F. Bolger Center, 9600
Newbridge Drive, Potomac, MD 20854.
Contact Person: James J. Li, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5148,
MSC 7849, Bethesda, MD 20892, 301–806–
8065, lijames@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Small
Business: Non-HIV Anti-Infective
Therapeutics.
Date: March 19–20, 2020.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Bethesda, 7335
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Bidyottam Mittra,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, Bethesda, MD 20894, 301–435–0000,
bidyottam.mittra@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Small
Business: Cardiovascular Sciences.
Date: March 19–20, 2020.
Time: 8:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites Alexandria Old
Town, 1900 Diagonal Road, Alexandria, VA
22314.
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
9791
Contact Person: Margaret Chandler, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4126,
MSC 7814, Bethesda, MD 20892, 301–435–
1743, margaret.chandler@nih.gov.
Name of Committee: AIDS and Related
Research Integrated Review Group, HIV
Immunopathogenesis and Vaccine
Development Study Section.
Date: March 19–20, 2020.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Fairmont Washington, DC, 2401
M Street NW, Washington, DC 20037.
Contact Person: Shiv A. Prasad, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5220,
MSC 7852, Bethesda, MD 20892, 301–443–
5779, prasads@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, PAR Panel:
Fogarty Global Brain Disorders.
Date: March 19–20, 2020.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites—Chevy Chase
Pavillion, 4300 Military Road NW,
Washington, DC 20015.
Contact Person: Suzan Nadi, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5217B,
MSC 7846, Bethesda, MD 20892, 301–435–
1259, nadis@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Exploration
of Antimicrobial Therapeutics and
Resistance.
Date: March 19–20, 2020.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road NW,
Washington, DC 20015.
Contact Person: Susan Daum, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3202,
Bethesda, MD 20892, 301–827–7233,
susan.boyle-vavra@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Small
Business: Endocrinology, Metabolism,
Nutrition and Reproductive Sciences.
Date: March 19, 2020.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Washington Marriott Georgetown,
1221 22nd Street NW, Washington, DC
20037.
Contact Person: Yunshang Piao, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institute of
Health, 6701 Rockledge Drive, Room 6184,
Bethesda, MD 20892, 301.402.8402, piaoy3@
mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Electronic
Nicotine Delivery Systems: Basic
Mechanisms of Health Effects—PAR Panel.
E:\FR\FM\20FEN1.SGM
20FEN1
]]>Agencies
[Federal Register Volume 85, Number 34 (Thursday, February 20, 2020)]
[Notices]
[Pages 9790-9791]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-03333]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Development of Clinical Outcome Assessments for
Clinical Trials in Substance Use Disorders as FDA-qualified Drug
Development Tools (U01 Clinical Trial Optional).
Date: March 6, 2020.
Time: 1:30 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center (NSC),
Building 6001 Executive Boulevard, Room 4235, Rockville, MD 20852
(Telephone Conference Call).
Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, National Institute
on Drug Abuse, National Institutes of Health, 6001 Executive
Boulevard, Room 4235, MSC 9550, Bethesda, MD 20892-9550, 301-827-
5819, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Workshops on the Use of Adolescent Brain Cognitive
Development (ABCD) Data (R25 Clinical Trial Not Allowed).
Date: March 16, 2020.
Time: 1:00 p.m. to 2:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center (NSC)
Building, 6001 Executive Boulevard, Room 4229, Rockville, MD 20852
(Telephone Conference Call).
Contact Person: Susan O. McGuire, Ph.D., Scientific Review
Officer, Office of Extramural Affairs, National Institute on Drug
Abuse, National Institutes of Health, 6001 Executive Boulevard, Room
4245, Rockville, MD 20852, 301-435-1426, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Research Networks for the Study of Recovery Support
Services for Persons Treated with Medications for Opioid Use
Disorder (R24 Clinical Trial Optional).
Date: March 17, 2020.
Time: 12:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center (NSC)
Building, 6001 Executive Boulevard, Room 4235, Rockville, MD 20852
(Telephone Conference Call).
Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, National Institute
on Drug Abuse, National Institutes of Health, 6001 Executive
Boulevard, Room
[[Page 9791]]
4235, MSC 9550, Bethesda, MD 20892-9550, 301-827-5819,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: February 13, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-03333 Filed 2-19-20; 8:45 am]
BILLING CODE 4140-01-P
